Table 6.
Intragranulocytic HSPA1A levels (ng/μg protein) according to genotype in the general population and stratified by risk groups
| AA | Pa | AC | Pa | CC | Pb | Pa | Pc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General population (N = 147) | General population (N = 211) | General population (N = 93) | |||||||||||
| 42.63 (4.64–124.75) | 42.10 (2.62–160.75) | 29.74 (1.56–92.27) | P < 0.001 | ||||||||||
| G0 (N = 74) | G1 (N = 59) | G2 (N = 14) | G0 (N = 107) | G1 (N = 76) | G2 (N = 28) | G0 (N = 58) | G1 (N = 26) | G2 (N = 10) | |||||
| 44.85 (4.64–97.08) | 45.77 (5.61–124.75) | 39.91 (16.16–87.53) | NS (P = 0.457) | 41.56 (2.62–107.01) | 43.15 (5.67–160.75) | 43.85 (12.48–81.45) | NS (P = 0.866) | 30.25 (1.56–90.83) | 26.48 (7.07–92.27) | 28.03 (7.92–88.41) | NS (P = 0.873) | P = 0.024 | |
Data are expressed as median (range)
aP: differences according to vascular risk group, the grouping variable being genotype (Kruskal–Wallis test, P = NS)
bP: differences according to genotype in the general population (Kruskal–Wallis test). Subjects with CC genotype showed significantly lower intragranulocytic HSPA1A concentrations than the other genotypes
cP: differences according to genotypes between groups (Kruskal–Wallis test). The decrease in intracellular HSPA1A concentration persisted in the CC genotype carriers, regardless of the vascular risk group they belong to